Profitability ratios measure the company ability to generate profitable sales from its resources (assets).
Paying user area
Try for free
Merck & Co. Inc. pages available for free this week:
- Statement of Comprehensive Income
- Common-Size Income Statement
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Reportable Segments
- Enterprise Value to FCFF (EV/FCFF)
- Price to FCFE (P/FCFE)
- Capital Asset Pricing Model (CAPM)
- Return on Assets (ROA) since 2005
- Analysis of Revenues
- Analysis of Debt
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Merck & Co. Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Profitability Ratios (Summary)
Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
The financial indicators over the periods presented reflect notable fluctuations and recovery patterns across profitability and efficiency ratios.
- Gross Profit Margin
- The gross profit margin shows a steady increase from the initial available data in March 31, 2020, at 67.74%, reaching 76.6% by June 30, 2025. This progression indicates an improving cost structure or higher pricing power, evidencing enhanced profitability at the gross level over the years with minor fluctuations.
- Operating Profit Margin
- The operating profit margin reveals more volatility. Beginning at 16.47% on March 31, 2020, it declines to a low of 3.92% by March 31, 2023, amidst a general downtrend in 2022 and early 2023. However, a recovery trend is apparent from mid-2023 onward, reaching 31.51% by June 30, 2025. These variations could be reflective of changes in operating expenses or fluctuations in other operating income components.
- Net Profit Margin
- Net profit margin follows a similar pattern to operating margin but exhibits smoother changes. After starting at 14.72% on March 31, 2020, it peaks at 29% by September 30, 2022, followed by a dip down to as low as 0.61% during September 30, 2023, and then rebounds to 27.27% by June 30, 2025. This indicates the influence of non-operating factors like taxes, interest, or extraordinary items affecting net profitability during certain periods.
- Return on Equity (ROE)
- The ROE shows considerable variability, starting at 27.91% in March 31, 2020, peaking at 38.34% by September 30, 2022, and subsequently plunging to 0.97% by September 30, 2023. Following this low, ROE recovers strongly and stabilizes in the mid-30% range by mid-2025. This suggests fluctuations in net income relative to shareholder equity, influenced by the net profit margins and possibly changes in equity structure or leverage.
- Return on Assets (ROA)
- The ROA trend mimics that of profitability indicators with a rise from 7.72% in March 31, 2020, to a peak of 15.48% in September 30, 2022, then a sharp drop to 0.34% by September 30, 2023. Subsequently, there is a recovery to around 15.14% by December 31, 2024, followed by a slight decline to 13.96% by June 30, 2025. The pattern suggests fluctuating efficiency in generating earnings from asset base, consistent with overall profit margin oscillations.
Overall, the data highlights a period of strong profitability growth until late 2022, followed by a significant contraction in 2023 across most margins and returns, before a partial recovery approaching 2025. This cyclical movement may suggest external economic impacts or company-specific operational challenges and subsequent corrective measures.
Return on Sales
Return on Investment
Gross Profit Margin
Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||||||
Gross profit | |||||||||||||||||||||||||||||
Sales | |||||||||||||||||||||||||||||
Profitability Ratio | |||||||||||||||||||||||||||||
Gross profit margin1 | |||||||||||||||||||||||||||||
Benchmarks | |||||||||||||||||||||||||||||
Gross Profit Margin, Competitors2 | |||||||||||||||||||||||||||||
AbbVie Inc. | |||||||||||||||||||||||||||||
Amgen Inc. | |||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | |||||||||||||||||||||||||||||
Danaher Corp. | |||||||||||||||||||||||||||||
Eli Lilly & Co. | |||||||||||||||||||||||||||||
Gilead Sciences Inc. | |||||||||||||||||||||||||||||
Johnson & Johnson | |||||||||||||||||||||||||||||
Pfizer Inc. | |||||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||||||
Vertex Pharmaceuticals Inc. |
Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q2 2025 Calculation
Gross profit margin = 100
× (Gross profitQ2 2025
+ Gross profitQ1 2025
+ Gross profitQ4 2024
+ Gross profitQ3 2024)
÷ (SalesQ2 2025
+ SalesQ1 2025
+ SalesQ4 2024
+ SalesQ3 2024)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
The gross profit value exhibits a general upward trend over the observed periods, with fluctuations that suggest seasonal or cyclical influences. Initially, there is a decline in gross profit from March 2020 to June 2020, followed by a rebound and steady increases thereafter, reaching a peak towards the end of 2024. Notably, the gross profit drops in late 2020 but recovers strongly in subsequent quarters, sustaining higher levels through 2023 and into 2024.
Sales figures demonstrate more volatility than gross profit but similarly trend upwards over time. Despite some quarters of decline, particularly around early 2021 and mid-2025, the sales values generally increase, peaking in late 2024. This increasing revenue trend supports the positive trajectory seen in gross profit, indicating effective revenue generation that outpaces early pandemic disruptions.
The gross profit margin, calculated as a percentage, is only visible from March 2021 onward and shows a steady and consistent improvement throughout the observed periods. Starting around 67.74%, the margin rises gradually each quarter, surpassing 75% by late 2024 and maintaining that level into mid-2025. This increasing margin implies either improved cost efficiency or favorable pricing power, contributing to stronger profitability independent of sales volume fluctuations.
- Gross Profit
- Showing a recovery from an early decline, the gross profit steadily increases with some seasonal variation, indicating resilience and growth in core profitability.
- Sales
- Sales figures reflect a stronger upward trend with periodic dips but overall growth, suggesting expanding market demand or successful business strategies during the periods analyzed.
- Gross Profit Margin
- The margin improves continuously from early 2021 onwards, indicating enhanced operational efficiency or pricing strategies, contributing positively to overall financial performance.
Operating Profit Margin
Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||||||
Operating income (loss) | |||||||||||||||||||||||||||||
Sales | |||||||||||||||||||||||||||||
Profitability Ratio | |||||||||||||||||||||||||||||
Operating profit margin1 | |||||||||||||||||||||||||||||
Benchmarks | |||||||||||||||||||||||||||||
Operating Profit Margin, Competitors2 | |||||||||||||||||||||||||||||
AbbVie Inc. | |||||||||||||||||||||||||||||
Amgen Inc. | |||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | |||||||||||||||||||||||||||||
Danaher Corp. | |||||||||||||||||||||||||||||
Eli Lilly & Co. | |||||||||||||||||||||||||||||
Gilead Sciences Inc. | |||||||||||||||||||||||||||||
Johnson & Johnson | |||||||||||||||||||||||||||||
Pfizer Inc. | |||||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||||||
Vertex Pharmaceuticals Inc. |
Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q2 2025 Calculation
Operating profit margin = 100
× (Operating income (loss)Q2 2025
+ Operating income (loss)Q1 2025
+ Operating income (loss)Q4 2024
+ Operating income (loss)Q3 2024)
÷ (SalesQ2 2025
+ SalesQ1 2025
+ SalesQ4 2024
+ SalesQ3 2024)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
The financial data over the reported periods reflect considerable fluctuations across key performance indicators, with evident volatility in operating income while sales show a generally upward trajectory. The operating profit margin data, partially available, further illuminate profitability dynamics.
- Operating Income (Loss)
- The operating income exhibits substantial variability, with several quarters recording negative values. Initially, in 2020, operating income starts on a positive note with figures above 3 billion USD in the first three quarters, followed by a significant loss of approximately 2.2 billion USD in the final quarter. Subsequently, operating income recovers and fluctuates, reaching peaks above 5 billion USD in multiple quarters, notably in March and September 2022. However, notable negative income returns in mid-2023 and late 2020, with losses exceeding 5 billion USD in one instance. In the most recent reported quarters of 2024 and 2025, operating income remains positive, generally ranging from approximately 3.9 billion to nearly 6 billion USD, suggesting recovery and sustained profitability despite past volatility.
- Sales
- Sales show an overall growth trend from early 2020 through 2025, starting around 12 billion USD and generally increasing to a range between 15.5 billion and 16.6 billion USD in later periods. Although some quarters exhibit slight declines, the longer-term trend reflects expansion in revenue generation, with peaks surpassing 16 billion USD in certain quarters. This sustained revenue growth amidst fluctuating operating income indicates potential changes in cost structures or other expense factors affecting profitability.
- Operating Profit Margin
- The operating profit margin data, available from late 2020 onwards, reveals important insights into profitability efficiency relative to sales. Margins fluctuate significantly over the periods, ranging from lows near 3.9% to highs above 33%. Early available data shows margins between 10% and 16%, with a notable increase reaching above 30% in several quarters of 2022. However, margins dip sharply in mid-2023 to below 14% and as low as 3.92%, corresponding with operating losses recorded. More recently, margins recover to the 21% to 31% range, indicating a resurgence in operational profitability. The fluctuations suggest that while sales volumes have grown, cost controls or expense volatility largely impact margin performance over time.
Overall, the data indicate a company navigating through episodic challenges impacting operating income and profitability margins, despite a positive sales growth trend. Continued attention to cost management and operational efficiencies appears critical to converting strong sales into consistent profitability.
Net Profit Margin
Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||||||
Net income (loss) attributable to Merck & Co., Inc. | |||||||||||||||||||||||||||||
Sales | |||||||||||||||||||||||||||||
Profitability Ratio | |||||||||||||||||||||||||||||
Net profit margin1 | |||||||||||||||||||||||||||||
Benchmarks | |||||||||||||||||||||||||||||
Net Profit Margin, Competitors2 | |||||||||||||||||||||||||||||
AbbVie Inc. | |||||||||||||||||||||||||||||
Amgen Inc. | |||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | |||||||||||||||||||||||||||||
Danaher Corp. | |||||||||||||||||||||||||||||
Eli Lilly & Co. | |||||||||||||||||||||||||||||
Gilead Sciences Inc. | |||||||||||||||||||||||||||||
Johnson & Johnson | |||||||||||||||||||||||||||||
Pfizer Inc. | |||||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||||||
Vertex Pharmaceuticals Inc. |
Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q2 2025 Calculation
Net profit margin = 100
× (Net income (loss) attributable to Merck & Co., Inc.Q2 2025
+ Net income (loss) attributable to Merck & Co., Inc.Q1 2025
+ Net income (loss) attributable to Merck & Co., Inc.Q4 2024
+ Net income (loss) attributable to Merck & Co., Inc.Q3 2024)
÷ (SalesQ2 2025
+ SalesQ1 2025
+ SalesQ4 2024
+ SalesQ3 2024)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
- Net Income (Loss) attributable to Merck & Co., Inc.
- The net income figures exhibit notable volatility over the observed periods. Initially, net income was positive in early 2020, with values around the 3,000 million USD mark, followed by a significant loss at the end of 2020 (-2,095 million USD). Subsequently, the net income rebounded, reaching a peak of 4,567 million USD in Q3 2021, but again experienced fluctuations including a pronounced loss in Q2 2023 (-5,975 million USD). In the most recent quarters, net income rebounded once more, peaking at 5,079 million USD in Q3 2025. The recurring spikes and troughs suggest periods of irregular profitability impacting the company's financial results.
- Sales
- Sales demonstrate an overall upward trend despite intermittent fluctuations. Starting at approximately 12,057 million USD in Q1 2020, sales decreased slightly mid-2020 but progressively increased, reaching 15,962 million USD by Q3 2023. Although some quarters show modest declines or plateaus, overall growth is observed, with sales exceeding 15,000 million USD in multiple recent periods. This steady revenue growth indicates strengthening market performance or successful product positioning over time.
- Net Profit Margin (%)
- The net profit margin displays variability but generally maintains a positive trajectory after early missing values. Margins peaked near 29% in Q3 2022 and fluctuated thereafter, dropping sharply to single digits and even below 1% in some quarters such as Q4 2022 and Q1 2023, correlating with noted periods of net losses. However, margins recovered to the 20-27% range in subsequent quarters, reflecting a restoration of profitability levels. The margin volatility aligns with the irregularities seen in net income, suggesting profit variability driven by either cost fluctuations, revenue changes, or one-time events.
- Overall Financial Patterns and Insights
- The financial data reveal a cyclical pattern of earnings volatility against a backdrop of generally rising sales revenue. While the company’s top-line performance shows growth resilience, net income and profitability margins suffer from periodic downturns, including substantial losses during specific quarters. This disparity indicates potential operational or market challenges affecting earnings quality despite steady sales. Recovery in net income and margins following losses suggests an ability to manage or overcome adverse impacts over time. Continuous monitoring of these fluctuations and underlying causes will be essential for assessing future financial stability and growth prospects.
Return on Equity (ROE)
Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||||||
Net income (loss) attributable to Merck & Co., Inc. | |||||||||||||||||||||||||||||
Total Merck & Co., Inc. stockholders’ equity | |||||||||||||||||||||||||||||
Profitability Ratio | |||||||||||||||||||||||||||||
ROE1 | |||||||||||||||||||||||||||||
Benchmarks | |||||||||||||||||||||||||||||
ROE, Competitors2 | |||||||||||||||||||||||||||||
AbbVie Inc. | |||||||||||||||||||||||||||||
Amgen Inc. | |||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | |||||||||||||||||||||||||||||
Danaher Corp. | |||||||||||||||||||||||||||||
Eli Lilly & Co. | |||||||||||||||||||||||||||||
Gilead Sciences Inc. | |||||||||||||||||||||||||||||
Johnson & Johnson | |||||||||||||||||||||||||||||
Pfizer Inc. | |||||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||||||
Vertex Pharmaceuticals Inc. |
Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q2 2025 Calculation
ROE = 100
× (Net income (loss) attributable to Merck & Co., Inc.Q2 2025
+ Net income (loss) attributable to Merck & Co., Inc.Q1 2025
+ Net income (loss) attributable to Merck & Co., Inc.Q4 2024
+ Net income (loss) attributable to Merck & Co., Inc.Q3 2024)
÷ Total Merck & Co., Inc. stockholders’ equity
= 100 × ( + + + )
÷ =
2 Click competitor name to see calculations.
- Net Income (Loss) Attributable to the Company
- The net income values exhibit considerable volatility over the observed periods, with notable losses recorded in the quarters ending December 31, 2020, and June 30, 2023. Initially, the net income shows a fluctuating upward trend from March 31, 2020, to September 30, 2021, peaking at 4,567 million USD. This is followed by a sharp decline and a substantial loss of -5,975 million USD in June 2023. Subsequently, net income recovers with positive figures exceeding 4,000 million USD towards the end of 2023 and into 2024, demonstrating resilience despite interim setbacks.
- Total Stockholders’ Equity
- Stockholders’ equity shows a general upward trajectory throughout the periods, starting at 26,205 million USD on March 31, 2020, and reaching 48,993 million USD by June 30, 2025. This reflects growth in the company’s net assets despite some fluctuations. A downturn is observed during mid-2023, consistent with the drop in net income, but equity levels recover and continue to increase thereafter, indicating sustained value creation for shareholders.
- Return on Equity (ROE)
- Return on Equity exhibits high variability, corresponding closely with fluctuations in net income. From missing data in the early periods, ROE is reported starting at 27.91% in March 31, 2021, with values oscillating between a high of 38.34% in September 30, 2022, and a low of 0.97% in March 31, 2024. These fluctuations indicate varying efficiency in generating returns from equity capital, with lower ROE values aligning with periods of negative or diminished profitability. The later quarters in 2024 and 2025 show a recovery and improvement in ROE, reaching above 30%, suggesting enhanced performance and profitability relative to shareholders' equity.
Return on Assets (ROA)
Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||||||
Net income (loss) attributable to Merck & Co., Inc. | |||||||||||||||||||||||||||||
Total assets | |||||||||||||||||||||||||||||
Profitability Ratio | |||||||||||||||||||||||||||||
ROA1 | |||||||||||||||||||||||||||||
Benchmarks | |||||||||||||||||||||||||||||
ROA, Competitors2 | |||||||||||||||||||||||||||||
AbbVie Inc. | |||||||||||||||||||||||||||||
Amgen Inc. | |||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | |||||||||||||||||||||||||||||
Danaher Corp. | |||||||||||||||||||||||||||||
Eli Lilly & Co. | |||||||||||||||||||||||||||||
Gilead Sciences Inc. | |||||||||||||||||||||||||||||
Johnson & Johnson | |||||||||||||||||||||||||||||
Pfizer Inc. | |||||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||||||
Vertex Pharmaceuticals Inc. |
Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q2 2025 Calculation
ROA = 100
× (Net income (loss) attributable to Merck & Co., Inc.Q2 2025
+ Net income (loss) attributable to Merck & Co., Inc.Q1 2025
+ Net income (loss) attributable to Merck & Co., Inc.Q4 2024
+ Net income (loss) attributable to Merck & Co., Inc.Q3 2024)
÷ Total assets
= 100 × ( + + + )
÷ =
2 Click competitor name to see calculations.
The analysis of the quarterly financial data indicates significant fluctuations in net income attributable to the company over the observed periods. Initially, net income showed moderate values, with a notable loss in the quarter ending December 31, 2020. Subsequently, net income rebounded strongly in 2021, reaching peaks particularly in the third quarter of 2021. The year 2022 maintained positive net income figures, although with a gradual decline towards the end of the year. The first quarter of 2023 experienced another sharp decrease, registering a substantial loss. Following this, net income resumed a recovery trend through 2023 and into 2024, with several quarters showing strong income values exceeding prior averages.
Total assets have generally exhibited an upward trend throughout the period, increasing from around 84.9 billion US dollars at the beginning of 2020 to over 117 billion US dollars by mid-2024. Some fluctuations occurred, including a noticeable increase between late 2020 and 2022, suggesting investment activities or asset growth that continued into 2024.
Return on assets (ROA) presents a variable pattern, with data available from the quarter ending December 31, 2020. Initial ROA values ranged between 6 and 8%, followed by a substantial increase between early 2021 and late 2022, where ROA reached levels above 12%, peaking around 15.5% in the third quarter of 2022. A marked decline occurred in early 2023, with ROA dropping sharply to below 3%, then further diminishing in some quarters before recovering towards the end of 2023 and again in 2024. ROA values in 2024 generally hovered between approximately 10% and 15%, indicating improved asset efficiency compared to early 2023 but still reflecting some volatility.
Overall, the data reflects periods of volatility in profitability metrics, with recurring sharp declines interspersed with sustained recoveries. Asset growth has been steady and consistent, supporting operational capacity. Efficiency, as indicated by ROA, has mirrored the fluctuations in net income but shows signs of resilience and recovery in the more recent quarters analyzed.
- Net Income Trends
- Marked by significant volatility including sharp losses in late 2020 and early 2023, counterbalanced by periods of strong profitability especially in late 2021 and most of 2022 and mid-2024.
- Total Assets Movement
- Generally rising trend reflecting asset accumulation or investment, growing from approximately 85 billion to over 117 billion US dollars between early 2020 and mid-2024.
- Return on Assets (ROA) Fluctuation
- ROA improved substantially from late 2020 through 2022, peaked mid-2022, fell sharply in early 2023, and recovered but remained volatile through 2024.
- Operational Insights
- Volatility in net income alongside steady asset growth suggests potential external or operational challenges impacting profitability intermittently, while asset base expansion supports longer-term capacity.